BLGO BioLargo

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available.

The interview featuring an overview of BLGO’s current news and moves can be heard at .

Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s business model and market segments with SmallCapVoice.com. With a wide array of issued patents, an extensive R&D talent pool, and a full-service engineering team, the company maintains a robust pipeline of products from inception through maturity.  BioLargo monetizes its technology assets with the goal of maximizing both impact and shareholder value, using licensing, strategic partnership, and direct-to-market strategies.

Recently, the Company’s patented CupriDyne® technology has been proven in a third-party study to be effective in inactivating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. In addition, BioLargo announced in May 2020 that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic, has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.

In the interview, Calvert commented, “As the [COVID-19] pandemic took hold, our teams had to ask themselves, ‘how do we make a difference’. At each level, our operating units took a deep dive looking at our portfolio of technologies and assets to come up with our unique responses. This has been the busiest, most intense, but also most unifying time for our team in the history of the Company. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (). Our industrial odor control division, Odor-No-More () features CupriDyne Clean Industrial Odor Eliminator (), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water () develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and licensor to our subsidiary Clyra Medical (), which features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit .

Socialize with SmallCapVoice and their clients at;

Facebook:   

Twitter:    

Instagram:

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

For SmallCapVoice.com:

Stuart T. Smith

512-267-2430

Source: SmallCapVoice.com

 

EN
08/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioLargo

Sean Conroy
  • Sean Conroy

BioLargo - Firing on all cylinders

BioLargo reported $666,000 in total Q320 sales (+24.7% y-o-y), a new record, a $1.9m operating loss (flat year-on-year) and a $2.39m net loss (from $3.89m in Q319). It had $356,000 in Q320 sales from ONM Environmental, down 10% from Q319, but the division recovered significantly since the start of the pandemic (up 19% from Q120). Sequentially, companywide revenue growth was up 56% over Q220, a strong bounce back from COVID-19 disruptions, and total sales are up 15% for 9M20 to $1.52m. BioLargo a...

Sean Conroy
  • Sean Conroy

BioLargo - Clyraguard to be a major growth driver

BioLargo stated that it expects Clyra Medical (of which it owns a 48% interest) and its Clyraguard product to be a major driver of growth in the coming periods. Clyra Medical signed an agreement with a major national distributor in July, with the first substantial sales to occur in Q320. Clyra Medical reported a small revenue ($21,000) for Q220, reflecting one week of sales from a previous test marketing run.

 PRESS RELEASE

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Upda...

Dennis P. Calvert, President & CEO of BioLargo, Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com AUSTIN, Texas, June 08, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioLargo, Inc. (OTCQB:BLGO)(“the Company”), developer of sustainable technologies and a full-service environmental engineering company, today announced that a new audio interview with the Company is now available. The interview featuring an overview of BLGO’s current news and moves can be heard at . Dennis P. Calvert, President & CEO of BioLargo, discussed the Company’s bu...

Sean Conroy
  • Sean Conroy

BioLargo - Clyra launches Clyraguard

Clyra Medical, BioLargo’s partially owned (36%) subsidiary, recently announced that it registered with the FDA and launched Clyraguard, a disinfectant marketed for the treatment of non-critical surfaces such as personal protective equipment (PPE) that is non-irritating to skin. Concurrent with this BioLargo announced the results of two studies that showed Clyraguard and the company’s environmental product CupriDyne could both fully inactivate COVID-19.

Sean Conroy
  • Sean Conroy

BioLargo - A record-setting year

BioLargo reported record revenue of $1.86m for 2019, a 36% increase over 2018 and a record single quarter revenue of over $560,000 for Q4. Odor-no-More (ONM) had its best year to date with $1.46m in revenue ($832,000 gross profit). However, ONM fell short of its goal of breaking even for the year with a loss of $337,000 (albeit improved from the 2018 $433,000 loss) due to increased headcount for future growth. The company noted that in 2020 it will focus on increasing sales through improved dist...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch